Navigation Links
CorMatrix(R) ECM(TM) Receives CE Mark for Cardiac Tissue Repair
Date:6/15/2010

ATLANTA, June 15 /PRNewswire/ -- CorMatrix® Cardiovascular, a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today it has received CE mark for its CorMatrix ECM for Cardiac Tissue Repair. With this designation, CorMatrix is now able to market this product in European Union countries.

"This CE mark will allow surgeons in Europe to expand their use of CorMatrix ECM to patients needing cardiac tissue repair," said Beecher Lewis, President and Chief Operating Officer, CorMatrix. "We believe this additional indication will allow us to significantly expand our presence outside of the United States and drive growth in key markets."

CorMatrix's ECM for Cardiac Tissue Repair is used to repair heart structures during open heart surgery – such as closing a hole in the heart (known as atrial septal defect or ASD). During surgery, CorMatrix ECM is sutured onto the heart tissue in need of repair. It then serves as a scaffold, enabling the body's own cells to infiltrate and ultimately replace and remodel the implanted ECM with native tissue. The anatomy is restored naturally through the course of the body's innate wound healing process. It works differently than other available surgical materials, as CorMatrix ECM allows for repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can result in unwanted effects.

"Through my experience using CorMatrix ECM for pericardial closure procedures, we've seen that it supports native tissue repair and provides favorable outcomes for patients," said Prof. Giovanni Stellin, Chief pediatric cardiac surgeon at the University of Padova. "The cardiac tissue repair product will be a welcome addition to our surgical protocol."

Surgeons attending the International Society for Minimally Invasive Cardiovascular Surgery (ISMICS) meeting in Berlin, June 16-19, 2010, may hear more about CorMatrix ECM by visiting booth #6293 or during two poster presentations featuring CorMatrix ECM Technology on Thursday, June 17.

CorMatrix ECM Technology has been commercially available in the U.S. since 2006 and has been implanted in nearly 20,000 cardiac surgery procedures at more than 300 hospitals in the U.S.

About CorMatrix ECM Technology

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark for its ECM Technology as an implant for pericardial closure and for use in cardiac tissue repair.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative cardiovascular devices that harness the body's innate ability to remodel damaged tissue. For more information, visit www.cormatrix.com.


'/>"/>
SOURCE CorMatrix Cardiovascular, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
2. CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
(Date:6/24/2016)... ... , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event ... that have been wounded in battle and their families. Venture Construction Group is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... To succeed ... Most providers, however, are unsure how to move forward, given the need to ... a path forward tailored to an organization’s specific needs. , PYA Principal Martie ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Seema Daulat, a native Texan and ... South Lamar location as of July 13, 2016. , Dr. Daulat earned her Doctorate ... student, she regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, a Texas-based insurance ... and the surrounding region, is initiating a charity drive to assist a student to ... for a scholarship fund that will be presented to the chosen student to help ...
Breaking Medicine News(10 mins):